Comprehensive genomic analysis of low-grade brain tumors sorts them into three categories, one of which has the molecular hallmarks and shortened survival of glioblastoma multiforme
Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research
Elite recognition for life-saving innovations of drug combinations, immunotherapy for cancer.
MD Anderson’s Allison honored; “Many cancer patients are alive today because of his vision”
Two champions of gender equality in medicine and research will be honored by The University of Texas MD Anderson Cancer Center at 4 p.m., today in MD Anderson’s Onstead Auditorium.
MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate to develop therapies that unleash patients’ immune systems to attack their cancers.
Computed tomography (CT) scans routinely taken to guide the treatment of pancreatic cancer may provide an important secondary benefit. According to new research from The University of Texas MD Anderson Cancer Center, the scans also reflect how well chemotherapy will penetrate the tumor, predicting the effectiveness of treatment.
Airways near lung tumors provide clues to genetics of cancer
For women with breast cancer undergoing radiation therapy, yoga offers unique benefits beyond fighting fatigue, according to research from The University of Texas MD Anderson Cancer Center.
Research at The University of Texas MD Anderson Cancer Center is finally unearthing some of the ancient mysteries behind leprosy, also known as Hansen’s disease, which has plagued mankind throughout history. The new research findings appear in the current edition of journal PLOS Neglected Tropical Diseases. According to this new hypothesis, the disease might be the oldest human-specific infection, with roots that likely stem back millions of years.
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.
Quality leaders outline action plan for national oversight, collaboration and patient-centered approaches
Today, CVS Caremark, the company that operates 7,600 CVS stores nationwide, announced the bold decision to stop selling tobacco products before the end of the year. The University of Texas MD Anderson Cancer Center applauds this decision. MD Anderson President Ron DePinho, M.D., today released the following statement.
When comparing treatments designed to enable long-term breast preservation for older women with invasive breast cancer, researchers found those treated with brachytherapy were at higher risk for a later mastectomy, compared to women treated with standard radiation therapy.
The once sketchy landscape of the molecular defects behind bladder cancer now resembles a road map to new, targeted treatments thanks to the unified efforts of scientists and physicians at 40 institutions.
Two proteins compete for one binding site with metastasis at stake
The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.
Fifty years ago this month, The U.S. Surgeon General jumpstarted America’s efforts to combat lung cancer and other diseases caused by smoking with the release of the 1964 U.S. Surgeon General’s Report on Smoking and Health.
IMRT reduces side effects, also improves outcomes
A simple blood test that can locate gene defects associated with cancer? New MD Anderson research suggests the technology may not be too far off
Pfizer and MD Anderson sign first agreement to advance cancer immunotherapy through MD Anderson's Moon Shots Program immunotherapy platform
Freeing the immune system to track down and kill tumors is helping a widening circle of patients.
Basic science research that exposed vital details of cancer’s defense against the immune system, revealing an entirely new way to combat these diseases, has earned Jim Allison, Ph.D., a Breakthrough Prize in Life Sciences.
Abstract #P3-06-02
Drug combination reins in follicular lymphoma.
PKM2 controls mitosis, saving cancer cells from death and promoting brain tumor growth
A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research led by scientists at The University of Texas MD Anderson Cancer Center published online at Nature Cell Biology this week.
Andreeff, Do, Dmitrovsky and Wood honored for distinguished scientific efforts.
Phase III trial examines pathological complete response rate
Lung cancer is the number one cancer killer in the U.S., causing more deaths than the next three most common cancers – colon, breast and prostate – combined. Worldwide, lung cancer accounts for 1.3 million deaths annually. An estimated $10.3 billion per year is spent in the U.S. on lung cancer treatment alone, yet those diagnosed with the disease have just a 15 percent survival rate.
James Allison wins @TheEconomist 2013 Innovation Award for bioscience.
Tobacco misconceptions prevail in the United States despite the dramatic drop in smoking rates since the release of the first Surgeon General’s Report on smoking and health in January 1964. Experts at The University of Texas MD Anderson Cancer Center dispel common myths and share new educational resources to address this persistent challenge.
Two leaders at The University of Texas MD Anderson Cancer Center have been elected to the Institute of Medicine (IOM) of the National Academies in recognition of their contributions to medical science and health care.
Children of melanoma survivors were more likely to wear hats and re-apply sunscreen after receiving a multi-media informational program designed specifically for them. These new findings were included in research published in the journal of Cancer Epidemiology, Biomarkers and Prevention – a publication of the American Association for Cancer Research.
NIH awards MD Anderson anti-asthma project.
Commentary in Nature Genetics describes the new initiative and its potential implications for cancer research and future treatment.
A new study from researchers at The University of Texas MD Anderson Proton Therapy Center found that the use of feeding tubes in oropharyngeal carcinoma (OPC) cancer patients treated with intensity modulated proton therapy (IMPT) decreased by more than 50 percent compared to patients treated with intensity modulated radiation therapy (IMRT). This suggests that proton therapy may offer vital quality of life benefits for patients with tumors occurring at the back of the throat.
Broad, deep and outstanding research in cancer science, treatment and prevention have earned The University of Texas MD Anderson Cancer Center a $48.6-million, five-year grant from the National Cancer Institute and an “exceptional” ranking, the highest possible, from the NCI’s extensive peer-review process.
A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor’s ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.
A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy, an international team lead by researchers at The University of Texas MD Anderson Cancer Center reported online today in the journal Cancer Cell.
CA-125, the protein long-recognized for predicting ovarian cancer recurrence, now shows promise as a screening tool for early-stage disease by evaluating its change over time , according to researchers at The University of Texas MD Anderson Cancer Center.
A smoking-cessation intervention delivered through mobile phones to HIV/AIDS-positive smokers increased cessation rates compared to standard care, according to research published online in Clinical Infectious Diseases.
With the third and largest of the U.S. tobacco companies planning an e-cigarette product launch this fall, this next frontier for “Big Tobacco” provides renewed presence in a declining marketplace.
An app to prevent teens from smoking and encourage them to quit if they’ve started is now just a few taps away and available free on the Apple iTunes Store.
A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson Cancer Center report this week in the Early Edition of the Proceedings of the National Academy of Sciences (PNAS).
MD Anderson scientists targeted drug for prime cancer- promoter
Scientists find origins of organ-destroying fibrosis.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right